more_reports

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

Biotech Firm Clears Major U.S. Trading Hurdle

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) just gained DTC eligibility, opening the door for faster U.S. trades and broader investor access. With AI-driven cancer drugs in development, analysts are taking notice. Read more to find out why.
Tags: Biotechnology / Pharmaceuticals

Biotech Partnership to Revolutionize Diabetes Treatment

  ()
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) announces a collaborative research agreement with Eledon Pharmaceuticals Inc. to assess Eledon's immunosuppressive drug in Sernova's ongoing trials of its cell pouch biohybrid organ for patients with Type 1 diabetes (T1D).
Tags: Biotechnology / Pharmaceuticals

AI Healthtech Firm Partners with EngageWell and CVS Health Foundation on NYC Senior Care Initiative

  ()
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) launches virtual screening for older adults in NYC, backed by US$1M from CVS Health Foundation, as it scales AI tools and patient reach. Read more about how this initiative is helping expand access to care and driving growth in virtual health innovation.
Tags: Biotechnology / Pharmaceuticals

Biopharma Firm Assembles Elite AI Cancer Team

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) strengthens its AI-driven cancer program with a world-class advisory board and breakthrough drug discovery platforms. Read more about how Rakovina's expert-backed strategy and proprietary platforms support next-gen oncology drug development and potential licensing deals.
Tags: Biotechnology / Pharmaceuticals

Canadian Biotech Targets Massive Cell Technology Gains

Research Report
  ()
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) recently announced a partnership with Eledon Pharmaceuticals Inc. (ELDN:NASDAQ) to explore the utility of Eledon's clinical-stage anti-CD40L monoclonal antibody tegoprubart/AT-1501 for conferring sustainable immune evasion of pancreatic islets deployed into Sernova's Cell Pouch device. Read on to see why one Leede Financial Inc. analyst rates this stock as a Speculative Buy.
Tags: Biotechnology / Pharmaceuticals

Biotech Co. Still a Buy Despite Manufacturing Setbacks

Research Report
  ()
While it received a lower price target due to manufacturing setbacks, Jasper Therapeutics Inc. (JSPR:NASDAQ) is still a Buy, according to an H.C. Wainwright & Co. research note.
Tags: Biotechnology / Pharmaceuticals

Vaccine Co. Secures European Regulatory Breakthrough Potential

Research Report
  ()
GeoVax Labs Inc. (GOVX:NASDAQ) recently raised US$6 million, projected to find operations through the last quarter of 2025, according to a ROTH Capital Markets research note. The company also received highly favorable guidance for GEO-MVA, its prophylactic vaccine for Mpox and smallpox from The European Medicines Agency.
Tags: Biotechnology / Pharmaceuticals

Biotech Firm Adjusts Placement Terms to Fuel U.S. Expansion

  ()
Canadian healthcare and clinical stage drug development company Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) updates the pricing and warrant terms for its previously announced non-brokered private placement. Read why one technical analyst thinks the stock is ready to break out.
Tags: Life Sciences Tools & DiagnosticsBiotechnology / PharmaceuticalsPsychedelics

Biotech Company Finds DNA-Targeting Drugs with AI in Canada

  ()
Biopharmaceutical company Rakovina Therapeutics Inc. (RKV:TSX.V) shared AGM results and key AI-driven cancer drug milestones in Vancouver. Read why some analysts are seeing a 300% potential return
Tags: Biotechnology / Pharmaceuticals

Analyst Has Confidence in Biotech's Path

Research Report
  ()
Vertex Pharmaceuticals Inc.'s (VRTX:NASDAQ) updated data is "a strong positive read-through for Sernova and help de-risk the broader field of cell-based therapies in T1D," according to an H.C. Wainwright & Co. research note.
Tags: Biotechnology / Pharmaceuticals

Isotope Co. Discovers Uranium-Helium Breakthrough Potential

  ()
ASP Isotopes Inc. (ASPI:NASDAQ) is seeing at least two major transformative developments this month. Read why one analyst sees these events as positive.
Tags: UraniumTechnologySpecial SituationsBiotechnology / Pharmaceuticals

Sirens of High Finance

Contributed Opinion
  ()
Michael Ballanger of GGM Advisory Inc. shares his take on the current state of the market and reviews one copper stock he has been betting on for a while.
Tags: TechnologyCritical MetalsBiotechnology / PharmaceuticalsGold

California Biotech's Trial Shows Encouraging Results

Research Report
  ()
Kura Oncology Inc.'s (KURA:NASDAQ) KOMET-007 trial results, supporting ziftomenib's benefit-risk profile for first-line acute myeloid leukemia, were encouraging, according to an H.C. Wainwright & Co. research note.
Tags: Biotechnology / Pharmaceuticals

Orogen: End of Another Chapter Draws Near

Contributed Opinion
  ()
Global Analyst Adrian Day discusses developments at some companies on his list, including Orogen Royalties Inc. (OGN:TSXV; OGNRF:OTCQX) and Franco-Nevada Corp. (FNV:TSX; FNV:NYSE).
Tags: SilverGoldBiotechnology / Pharmaceuticals

Q1/25 Financials of Cancer Drug Developer Released

Research Report
  ()
Rakovina Therapeutics Inc.'s (RKV:TSX.V) CA$4 million equity offering is nearing completion, noted a Leede Financial Inc. report.
Tags: Biotechnology / Pharmaceuticals

Biotech Firm Unveils Diabetes Breakthrough in Canada

  ()
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) advanced its Cell Pouch device in Canada with insulin-free outcomes in all trial patients and a CA$6 target price from analysts. Read more to find out how expert advisors, international funding, and a next-gen clinical pipeline could reshape treatment for type 1 diabetes.
Tags: Biotechnology / Pharmaceuticals

New RA Drug Shown to Work, Be Safe

Research Report
  ()
"Efficacy at six months represented a 'best case' scenario, in our view," and "safety was very favorable," noted a Wedbush report.
Tags: Biotechnology / Pharmaceuticals

Analyst Likes Co. Developing Immuno-oncology Drugs

Research Report
  ()
There are multiple reasons to be bullish on this undervalued stock with significant potential upside, noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

Co.'s New Cancer Drug Shows Promise

Research Report
  ()
Preclinical results support this asset's dual mechanism of action in abating cancer drug resistance and reversing cancer-induced immune suppression, noted a D. Boral Capital report.
Tags: Biotechnology / Pharmaceuticals

Biotech Co. Reaches MS Clinical Program Milestones

Research Report
  ()
These include release of additional Phase 2 trial data and completion of enrollment for two separate Phase 3 studies, noted a D. Boral Capital report.
Tags: Biotechnology / Pharmaceuticals

Phase 2b Trial Data on Treatment for Inflammation Due Soon

Research Report
  ()
These results are expected to be favorable based on positive results of a recent interim study, noted a ROTH Capital Partners report.
Tags: Biotechnology / Pharmaceuticals

Canadian Biotech Advances High-Impact DDR Programs

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) secures CA$4M in strategic funding, boosts AI-powered cancer programs, and eyes 300% potential return with DDR breakthroughs. Read more about the companys scientific momentum, analyst coverage, and AI-driven oncology strategy.
Tags: Biotechnology / Pharmaceuticals

Biotech Company Unlocks Gene Therapy Breakthrough in Canada

  ()
PreveCeutical Preventive Health Sciences (PREV:CSE; PRVCF:OTC; 18H:FSE) moves gene and pain therapy assets into new entities in Canada, with proof-of-concept studies signaling major delivery breakthroughs. Find out how the company's strategy to form independent entities and leverage proprietary delivery platforms is positioning it for growth across multiple therapeutic markets.
Tags: Biotechnology / Pharmaceuticals

Data Readout Positive from Trial of New Schizophrenia Drug

Research Report
  ()
This new dopamine-serotonin system modulator showed sustained efficacy over 52 weeks and a favorable tolerability and safety profile, noted a D. Boral Capital report.
Tags: Biotechnology / Pharmaceuticals

Biotech Firm Gains Exclusive Alzheimer's Rights in U.S. and Canada

  ()
Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) secures exclusive Alzheimer's clinic rights in Canada and key U.S. cities, positioning for a high-growth breakthrough. Learn how Algernon plans to launch cutting-edge clinics featuring PET scan technology and expand into a multibillion-dollar diagnostics market
Tags: Biotechnology / Pharmaceuticals

Showing Results: 26 to 50 of 57 Prev Next